Gastroesophageal Reflux Disease (GERD) Therapeutics Market Analysis By Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro-Kinetic Agents), By Region, And Segment Forecasts, 2014 - 2025

  • ID: 4118788
  • Report
  • 80 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Abbott
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pfizer, Inc.
  • MORE
The global Gastroesophageal Reflux Disease (GERD) therapeutics market is expected to reach USD 4.34 billion by 2025. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime.

The overall market has been experiencing a downturn in terms of revenue in the past several years as the leading drugs for GERD treatment have lost their patent protection, with their market shares now largely consumed by over-the-counter (OTC) and generic medications. Although loss of exclusivity of high-grossing drugs have caused a market fall-off, the demand for acid reducing drugs due to the high prevalence and incidence levels of GERD will prove beneficial to the industry from a commercial standpoint.

GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives, but also extends to the healthcare system and economy.

In addition, the occurrence of acid reflux disease increases with age, rendering elderly people more prone to developing a severe form of heartburn. The geriatric subset hence forms a prominent target population for GERD therapeutics.

Further key findings from the study suggest:

Antacids have been identified as the largest drug type segment in terms of revenue share due to their cost-effectiveness and greater consumer accessibility

The rising trend of self-medication in case of heartburn is particularly responsible for the growth in sales of OTC antacids

Proton pump inhibitors accounted for the second largest segment as they are the most commonly prescribed medication for the treatment of acid reflux

Market share of proton pump inhibitors is expected to decline over the forecast period with the loss of patent protection of several leading drugs, such as Nexium and Prilosec, in this segment

North America accounted for the largest regional market in 2016 owing to the presence of a large patient population suffering from heartburn and the availability of OTC generics

On the other hand, Asia Pacific is expected to grow at a fairly high growth rate as compared to other regional markets due to increased adoption of OTC and generic antacids along with rising prevalence of heartburn
PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pfizer, Inc.
  • MORE
1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database
1.1.2 Internal Database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise Market Calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based Segment Share Calculation
1.6 List of Secondary Sources
2 Executive Summary
2.1 Market Snapshot
3 GERD Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation&Scope
3.1.1 Market drivers analysis
3.1.2 Market Restraints Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 GERD therapeutics- SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
4 GERD Therapeutics Market: Drug Type Estimates & Trend Analysis
4.1 GERD Therapeutics Market: Drug type movement analysis
4.2 Antacids
4.2.1 Antacids market, 2014 - 2025 (USDMillion)
4.3 H2 Receptor Blockers
4.3.1 H2 receptor blockers market, 2014 - 2025 (USDMillion)
4.4 Proton Pump Inhibitors
4.4.1 Proton pump inhibitors market, 2014 - 2025 (USDMillion)
4.5 Pro-kinetic Agents
4.5.1 Pro-kinetic agents market, 2014 - 2025 (USDMillion)
5 GERD Therapeutics Market: Regional Estimates & Trend Analysis
5.1 GERD Therapeutics Market Share, by Region, 2015 & 2025
5.2 North America
5.2.1 North America GERD therapeutics market, 2014 - 2025 (USDMillion)
5.2.2 U.S
5.2.2.1 U.S GERD therapeutics market, 2014 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada GERD therapeutics market, 2014 - 2025 (USDMillion)
5.3 Europe
5.3.1 Europe GERD therapeutics market, 2014 - 2025 (USDMillion)
5.3.2 UK
5.3.2.1 UK GERD therapeutics market, 2014 - 2025 (USDMillion)
5.3.3 Germany
5.3.3.1 Germany GERD therapeutics market, 2014 - 2025 (USDMillion)
5.4 Asia Pacific
5.4.1 Asia Pacific GERD therapeutics market, 2014 - 2025 (USDMillion)
5.4.2 Japan
5.4.2.1 Japan GERD therapeutics market, 2014 - 2025 (USDMillion)
5.4.3 China
5.4.3.1 China GERD therapeutics market, 2014 - 2025 (USDMillion)
5.5 Latin America
5.5.1 Latin America GERD therapeutics market, 2014 - 2025 (USDMillion)
5.5.2 Brazil
5.5.2.1 Brazil GERD therapeutics market, 2014 - 2025 (USDMillion)
5.6 MEA
5.6.1 MEA GERD therapeutics market, 2014 - 2025 (USDMillion)
5.6.2 South Africa
5.6.2.1 South Africa GERD therapeutics market, 2014 - 2025 (USDMillion)
6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Takeda Pharmaceutical Co., Ltd.
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 AstraZeneca PLC
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 Eisai Co., Ltd.
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 GlaxoSmithKline PLC
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 Johnson & Johnson Services, Inc.
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Daewoong Pharmaceutical Co., Ltd
6.3.6.1 Company overview
6.3.6.2 Financial overview
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives
6.3.7 Ironwood Pharmaceuticals, Inc.
6.3.7.1 Company overview
6.3.7.2 Financial overview
6.3.7.3 Product benchmarking
6.3.7.4 Strategic initiatives
6.3.8 RaQualia Pharma, Inc.
6.3.8.1 Company overview
6.3.8.2 Financial overview
6.3.8.3 Product benchmarking
6.3.8.4 Strategic initiatives
6.3.9 SFJ Pharmaceuticals Group
6.3.9.1 Company overview
6.3.9.2 Financial overview
6.3.9.3 Product benchmarking
6.3.9.4 Strategic initiatives
6.3.10 SRS Pharmaceuticals Pvt. Ltd
6.3.10.1 Company overview
6.3.10.2 Financial overview
6.3.10.3 Product benchmarking
6.3.10.4 Strategic initiatives
6.3.11 Reckitt Benckiser Group PLC
6.3.11.1 Company overview
6.3.11.2 Financial overview
6.3.11.3 Product benchmarking
6.3.11.4 Strategic initiatives
6.3.12 Novartis AG
6.3.12.1 Company overview
6.3.12.2 Financial overview
6.3.12.3 Product benchmarking
6.3.12.4 Strategic initiatives
6.3.13 Pfizer, Inc.
6.3.13.1 Company overview
6.3.13.2 Financial overview
6.3.13.3 Product benchmarking
6.3.13.4 Strategic initiatives
6.3.14 Abbott
6.3.14.1 Company overview
6.3.14.2 Financial overview
6.3.14.3 Product benchmarking
6.3.14.4 Strategic initiatives

List of Tables

Table 1 Country share estimation
Table 2 North America GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 3 U.S. GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 4 Canada GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 5 Europe GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 6 UK GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 7 Germany GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 8 Asia Pacific GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 9 Japan GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 10 China GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 11 Latin America GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 12 Brazil GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 13 MEA GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
Table 14 South Africa GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)

List of Figures

Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Value chain-based sizing & forecasting
Figure 4 QFD modeling for market share assessment
Figure 5 Market summary, 2015
Figure 6 Market trends & outlook
Figure 7 Market segmentation & scope
Figure 8 Market driver relevance analysis (Current & future impact)
Figure 9 Market restraint relevance analysis (Current & future impact)
Figure 10 SWOT Analysis, By Factor (political & legal, economic and technological)
Figure 11 Porter’s Five Forces Analysis
Figure 12 Company Market Share Analysis - IVD Quality Control Market, 2015
Figure 13 GERD therapeutics market drug type outlook key takeaways
Figure 14 GERD therapeutics market: Drug type movement analysis
Figure 15 Global antacids market, 2014 - 2025 (USD Million)
Figure 16 Global H2 receptor blockers market, 2014 - 2025 (USD Million)
Figure 17 Global proton pump inhibitors market, 2014 - 2025 (USD Million)
Figure 18 Global pro-kinetic agents market, 2014 - 2025 (USD Million)
Figure 19 Regional market place: Key takeaways
Figure 20 Regional outlook, 2015 & 2025
Figure 21 North America GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 22 U.S. GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 23 Canada GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 24 Europe GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 25 UK GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 26 Germany GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 27 Asia Pacific GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 28 Japan GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 29 China GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 30 Latin America GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 31 Mexico GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 32 Brazil GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 33 MEA GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 34 South Africa GERD therapeutics market, 2014 - 2025 (USD Million)
Figure 35 Strategy framework
Figure 36 Participant categorization
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Takeda Pharmaceutical Co., Ltd.
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Daewoong Pharmaceutical Co., Ltd
  • Ironwood Pharmaceuticals, Inc.
  • RaQualia Pharma, Inc.
  • SFJ Pharmaceuticals Group
  • SRS Pharmaceuticals Pvt. Ltd
  • Reckitt Benckiser Group PLC
  • Novartis AG
  • Pfizer, Inc.
  • Abbott
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll